

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

COALITION FOR AFFORDABLE DRUGS X LLC,
Petitioner,

v.

ANACOR PHARMACEUTICALS, INC.,
Patent Owner.

Case No. IPR2015-01776
Patent No. 7,582,621

PATENT OWNER'S EXHIBIT LIST

LIST OF EXHIBITS

| Exhibit | Description |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2001 | FDA Approved Label for KERYDIN [®] (Rev. 3/2015) |
| 2002 | Fairchild <i>et al.</i> , <i>In Vitro Determination of Uptake, Retention, Distribution, Biological Efficacy, and Toxicity of Boronated Compounds for Neutron Capture Therapy: A Comparison of Porphyrins with Sulfhydryl Boron Hydrides</i> , <i>Cancer Res.</i> , vol. 50, pp. 4860-65 (1990) |
| 2003 | Charif <i>et al.</i> , <i>A Historical Perspective on Onychomycosis</i> , <i>Dermatol. Ther.</i> vol. 3, pp. 43-45 (1997) |
| 2004 | Heath <i>et al.</i> , <i>Fatty Acid Biosynthesis as a Target for Novel Antibacterials</i> , <i>Curr. Opin. Invest. Drugs</i> , vol. 5, pp. 146-53 (2004) |
| 2005 | Baldock <i>et al.</i> , <i>A Mechanism of Drug Action Revealed by Structural Studies of Enoyl Reductase</i> , <i>Science</i> , vol. 274, pp. 2107-10 (1996) |
| 2006 | Biobor, R.E.D. Facts, EPA-738-R-93-004 (June 1993), http://nepis.epa.gov/Exe/ZyPDF.cgi?Dockey=200009P5.PDF |
| 2007 | Lefkovits <i>et al.</i> , <i>Direct Thrombin Inhibitors in Cardiovascular Medicine</i> , <i>Circulation</i> , vol. 90, pp. 1522-36 (1994) |
| 2008 | Grassberger <i>et al.</i> , <i>Preparation and Antibacterial Activities of New 1,2,3-Diazaborine Derivatives and Analogs</i> , <i>J. Med. Chem.</i> , vol. 27, no. 8, pp. 947-53 (1984) |
| 2009 | Baldock <i>et al.</i> , <i>Mechanism of Action of Diazaborines</i> , <i>Biochem. Pharm.</i> , vol. 55, pp. 1541-49 (1998) |
| 2010 | Heindel <i>et al.</i> , <i>The Developmental Toxicity of Boric Acid in Mice, Rats, and Rabbits</i> , <i>Environ. Health Perspect.</i> , vol. 102, suppl. 7, pp. 107-12 (1994) |
| 2011 | Richardson, <i>Clinical Update: Proteasome Inhibitors in Hematologic Malignancies</i> , <i>Cancer Treatment Rev.</i> , vol. 29, suppl. 1, pp. 33-39 (2003) |

| Exhibit | Description |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2012 | Bross <i>et al.</i> , <i>Approval Summary for Bortezomib for injection in the Treatment of Multiple Myeloma</i> , Clin. Cancer Res., vol. 10, pp. 3954-64 (2004) |
| 2013 | Adams, <i>Proteasome Inhibitors as Therapeutic Agents</i> , Expert Opin. Ther. Patents, vol. 13, no. 1, pp. 45-57 (2003) |
| 2014 | Dorland's Illustrated Medical Dictionary, p. 211 (29th ed. 2000) |
| 2015 | Stedman's Medical Dictionary, p. 204 (27th ed. 2000) |
| 2016 | Random House Webster's Unabridged Dictionary, p. 209 (2nd ed. 2001) |
| 2017 | Jordon <i>et al.</i> , <i>Boric Acid Poisoning: A Report of a Fatal Adult Case from Cutaneous Use. A Critical Evaluation of the Use of This Drug in Dermatologic Practice</i> , JAMA Derm, vol. 75, pp. 720-28 (1957). |
| 2018 | Zhdankin <i>et al.</i> , <i>Synthesis and Structure of Benzoxaboroles: Novel Organoboron Heterocycles</i> , Tetrahedron Lett., vol. 40, pp. 6705-08 (1999) |
| 2019 | Triggle, <i>Pharmacological Receptors: A Century of Discovery—and More</i> , Pharm. Acta Helvetiae, vol. 74, pp. 79-84 (2000) |
| 2020 | Larsen <i>et al.</i> , <i>The Prevalence of Onychomycosis in Patients with Psoriasis and Other Skin Diseases</i> , Acta Derm. Venereol., vol 83, pp. 206-09 (2003) |
| 2021 | Tatsumi <i>et al.</i> , <i>Therapeutic Efficacy of Topically Applied KP-103 Against Experimental Tinea Unguium in Guinea Pigs in Comparison with Amorolfine and Terbinafine</i> , Antimicrobial Agents and Chemotherapy, vol. 46, no. 12, pp. 3797-3801 (2002) |
| 2022 | Osborne <i>et al.</i> , <i>Antifungal Drug Response in an In Vitro Model of Dermatophyte Nail Infection</i> , Med. Mycol., vol. 42, pp. 159-63 (2004) |
| 2023 | Favre <i>et al.</i> , <i>Comparison of In Vitro Activities of 17 Antifungal Drugs Against a Panel of 20 Dermatophytes by Using a Microdilution Assay</i> , J. Clin. Microbiol., vol. 41, no. 10, pp. 4817-19 (2003) |

| Exhibit | Description |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2024 | Sangster, <i>Octanol-Water Partition Coefficients of Simple Organic Compounds</i> , J. Phys. Chem. Ref. Data, vol. 18, pp. 1111-1227 (1989) |
| 2025 | Powers <i>et al.</i> , <i>Structure-Based Approach for Binding Site Identification on AmpC β-Lactamase</i> , J. Med. Chem., vol. 45, pp. 3222-34 (2002) |
| 2026 | Boric Acid, R.E.D. Facts, EPA-738-F-93-006 (Sept. 1993), http://archive.epa.gov/pesticides/reregistration/web/pdf/0024fact.pdf |
| 2027 | Vander Straten <i>et al.</i> , <i>Cutaneous Infections: Dermatophytosis, Onychomycosis, and Tinea Versicolor</i> , Infect. Dis. Clinics N. Am., vol. 17, pp. 87-112 (2003) |
| 2028 | (Intentionally Left Blank) |
| 2029 | Curriculum vitae of Mahmoud A. Ghannoum, Ph.D., E.M.B.A. |
| 2030 | Curriculum vitae of Paul J. Reider, Ph.D. |
| 2031 | Curriculum vitae of Howard I. Maibach, M.D., Ph.D. |
| 2032 | Transcript, Deposition of Narasimha Murthy, Ph.D. (May 4, 5, 6, and 12, 2016) |
| 2033 | Transcript, Deposition of Stephen B. Kahl, Ph.D. (April 7 and 8, 2016) |
| 2034 | Declaration of Paul J. Reider, Ph.D. |
| 2035 | Declaration of Mahmoud A. Ghannoum, Ph.D., E.M.B.A. |
| 2036 | Declaration of Majella Lane, Ph.D. |
| 2037 | Declaration of Howard I. Maibach, M.D., Ph.D. |
| 2038 | Fletcher <i>et al.</i> , <i>Onychomycosis: The Development of a Clinical Diagnostic Aid for Toenail Disease, Part I. Establishing Discriminating Historical and Clinical Features</i> , Brit. J. Dermatol., vol. 150, no. 4, pp. 701–05 (2004) |

| Exhibit | Description |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2039 | Kemna & Elewski, <i>A U.S. Epidemiologic Survey of Superficial Fungal Diseases</i> , J. Am. Acad. of Dermatol., vol. 35, no. 4, pp. 539–42 (1996) |
| 2040 | Shivakumar, Repka, & Murthy, <i>Transungual Drug Delivery: an Update</i> , J. Drug Del. Sci. Tech., vol. 24, no. 3, pp. 301–10 (2014) (Ex. 3 from Murthy Deposition) |
| 2041 | <u>Topical Nail Products and Ungual Drug Delivery</u> (S. Narasimha Murthy & Howard I. Maibach eds., 2013) (Ex. 4 from Murthy Deposition) |
| 2042 | Koo <i>et al.</i> , <i>Synthesis and Comparative Toxicology of a Series of Polyhedral Borane Anion-Substituted Tetraphenyl Porphyrins</i> , J. Med. Chem., vol. 50, pp. 820–27 (2007) |
| 2043 | Office of Toxic Substances, Environmental Protection Agency, “Preliminary Investigation of Effects on the Environment of Boron, Indium, Nickel, Selenium, Vanadium and Their Compounds,” EPA-56/2-75-005A (August 1975) <i>available at</i> http://nepis.epa.gov/Exe/ZyPDF.cgi/9101277V.PDF?Dockey=9101277V.PDF |
| 2044 | Van Proosdij-Hartzema, <i>Boriumverbindingen: Verleden, Heden en Toekomst</i> , Ned. T. Geneesk., vol. 110, no. 51, pp. 2260–69 (1966) with certified English translation |
| 2045 | Elewski <i>et al.</i> , <i>Efficacy, Safety and Tolerability of Topical Terbinafine Nail Solution in Patients with Mild-to-Moderate Toenail Onychomycosis: Results from Three Randomized Studies using Double-Blind Vehicle-Controlled and Open-Label Active-Controlled Designs</i> , J. Eur. Acad. Derm. & Vener., vol. 27, no. 3, pp. 287–94 (2013) |
| 2046 | Cecil Textbook of Medicine, (J. Claude Bennett & Fred Plum ed., 1996) |
| 2047 | Hay <i>et al.</i> , <i>Fungal (onychomycosis) and other Infections Involving the Nail Apparatus in Baran and Dawber’s Diseases of the Nails and their Management</i> , (R. Baran <i>et al.</i> , eds., 2001) |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.